Finding Description
Based on observation, interview, and record review, the facility failed to ensure the resident, and the resident's representative, were made aware of the risks and benefits associated with the use of psychotropic medications prior to the start of treatment for 1 (#32) of 21 sampled residents. Findings include:
During an observation on 6/4/25 at 1:05 p.m., resident #32 was ambulating from the dining room towards her room. The resident's gait was slow, and she was using a walker for support. Facility staff had to direct resident #32 towards her room.
Review of resident #32's physician orders showed the following psychotropic medications being given to the resident:
- 2/11/25 to 3/17/25, Seroquel 25 mg once daily, as needed, for sleeplessness or agitation
- 4/29/25 to 5/29/25, olanzapine 2.5 mg twice daily, as needed, for agitation; and,
- 5/2/25 to current, sertraline 50 mg daily for mild dementia with psychotic disturbance.
Review of resident #32's EHR, accessed between 6/2/25 and 6/5/25, failed to show documentation of the risks and benefits of using the above listed psychotropic medications.
During an interview on 6/5/25 at 7:20 a.m., staff member C stated they (the facility) were trying to, hash out a good process for completing the consent with risks and benefits before the psychotropic medication was started. Staff member C stated he was responsible for obtaining this documentation. Staff member C stated if he was out of the office, the forms did not consistently get done.
A request was made on 6/3/25, for the consent documents for the resident's Seroquel, olanzapine, and sertraline used for resident #32. None were received prior to the end of the survey.
During an observation on 6/4/25 at 1:05 p.m., resident #32 was ambulating from the dining room towards her room. The resident's gait was slow, and she was using a walker for support. Facility staff had to direct resident #32 towards her room.
Review of resident #32's physician orders showed the following psychotropic medications being given to the resident:
- 2/11/25 to 3/17/25, Seroquel 25 mg once daily, as needed, for sleeplessness or agitation
- 4/29/25 to 5/29/25, olanzapine 2.5 mg twice daily, as needed, for agitation; and,
- 5/2/25 to current, sertraline 50 mg daily for mild dementia with psychotic disturbance.
Review of resident #32's EHR, accessed between 6/2/25 and 6/5/25, failed to show documentation of the risks and benefits of using the above listed psychotropic medications.
During an interview on 6/5/25 at 7:20 a.m., staff member C stated they (the facility) were trying to, hash out a good process for completing the consent with risks and benefits before the psychotropic medication was started. Staff member C stated he was responsible for obtaining this documentation. Staff member C stated if he was out of the office, the forms did not consistently get done.
A request was made on 6/3/25, for the consent documents for the resident's Seroquel, olanzapine, and sertraline used for resident #32. None were received prior to the end of the survey.